Gene expression signature-based approach identifies a pro-resolving mechanism of action for histone deacetylase inhibitors
暂无分享,去创建一个
M. Perretti | J. Dalli | T Montero-Melendez | J Dalli | M Perretti | T. Montero-Melendez | T. Montero-Melendez | Mauro Perretti | Jesmond Dalli
[1] S. Hart,et al. Neutrophils: dead or effete? Cell surface phenotype and implications for phagocytic clearance , 2005, Cell Death and Differentiation.
[2] G. Fantuzzi,et al. Histone Hyperacetylation Is Associated with Amelioration of Experimental Colitis in Mice1 , 2006, The Journal of Immunology.
[3] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[4] R. Stam,et al. Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia , 2012, Leukemia.
[5] Monica L Guzman,et al. Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. , 2008, Blood.
[6] M. Perretti,et al. Spatial and Temporal Profiles for Anti-Inflammatory Gene Expression in Leukocytes during a Resolving Model of Peritonitis1 , 2006, The Journal of Immunology.
[7] M. Sweet,et al. Histone deacetylases as regulators of inflammation and immunity. , 2011, Trends in immunology.
[8] M. Perretti,et al. Annexin 1 and its bioactive peptide inhibit neutrophil-endothelium interactions under flow: indication of distinct receptor involvement. , 2006, Blood.
[9] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[10] Giuseppe Cirino,et al. Downstream gene activation of the receptor ALX by the agonist annexin A1. , 2010, PloS one.
[11] U. Rescher,et al. Annexin A1 released from apoptotic cells acts through formyl peptide receptors to dampen inflammatory monocyte activation via JAK/STAT/SOCS signalling , 2011, EMBO molecular medicine.
[12] R. Grigg,et al. Histone deacetylases are dysregulated in rheumatoid arthritis and a novel histone deacetylase 3-selective inhibitor reduces interleukin-6 production by peripheral blood mononuclear cells from rheumatoid arthritis patients. , 2012, Arthritis and rheumatism.
[13] Dian J. Cao,et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy , 2011, Proceedings of the National Academy of Sciences.
[14] S. Gordon,et al. Impaired phagocytic mechanism in annexin 1 null macrophages , 2006, British journal of pharmacology.
[15] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[16] Adriano G. Rossi,et al. Inflammatory Resolution: new opportunities for drug discovery , 2004, Nature Reviews Drug Discovery.
[17] G. Cagney,et al. Annexin-1 and Peptide Derivatives Are Released by Apoptotic Cells and Stimulate Phagocytosis of Apoptotic Neutrophils by Macrophages1 , 2007, The Journal of Immunology.
[18] Alexander A. Morgan,et al. Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.
[19] C. A. Bonjardim,et al. PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA‐PI3K/Akt‐dependent and NF‐κB‐independent manner , 2010, Journal of leukocyte biology.
[20] Justin Lamb,et al. The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.
[21] T. McKinsey. Targeting Inflammation in Heart Failure with Histone Deacetylase Inhibitors , 2011, Molecular medicine.
[22] L. Schwartz,et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] A. Ohtsuka,et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. , 2008, Osteoarthritis and cartilage.
[24] Z. Wen,et al. Discovery of Molecular Mechanisms of Traditional Chinese Medicinal Formula Si-Wu-Tang Using Gene Expression Microarray and Connectivity Map , 2011, PloS one.
[25] M. Teixeira,et al. Annexin A1 modulates natural and glucocorticoid‐induced resolution of inflammation by enhancing neutrophil apoptosis , 2012, Journal of leukocyte biology.
[26] John Savill,et al. Corpse clearance defines the meaning of cell death , 2000, Nature.
[27] C. Serhan. The resolution of inflammation: the devil in the flask and in the details , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[28] F. D’Acquisto,et al. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation , 2009, Nature Reviews Immunology.
[29] 那須 義久. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model , 2008 .
[30] Laurent Ozbun,et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.
[31] Paul A Clemons,et al. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.
[32] G. Fantuzzi,et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[33] Michael R. Elliott,et al. Clearance of apoptotic cells: implications in health and disease , 2010, The Journal of cell biology.
[34] M. Usami,et al. Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways. , 2010, Nutrition (Burbank, Los Angeles County, Calif.).
[35] C. Serhan,et al. Molecular Circuits of Resolution: Formation and Actions of Resolvins and Protectins1 , 2005, The Journal of Immunology.
[36] T. Golub,et al. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. , 2006, Cancer cell.
[37] A. Tosco,et al. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of annexin A1. , 2008, European journal of cancer.
[38] S. Marullo,et al. A novel calcium‐dependent proapoptotic effect of annexin 1 on human neutrophils , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[39] L. Altucci,et al. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. , 2011, Recent patents on anti-cancer drug discovery.
[40] Carl Nathan,et al. Nonresolving Inflammation , 2010, Cell.
[41] Dakang Xu,et al. HDACi: molecular mechanisms and therapeutic implications in the innate immune system , 2012, Immunology and cell biology.
[42] B. Fontanella,et al. Histone deacetylase inhibitor FR235222 sensitizes human prostate adenocarcinoma cells to apoptosis through up-regulation of Annexin A1. , 2010, Cancer letters.
[43] M. Paul-Clark,et al. The FASEB Journal express article 10.1096/fj.02-0239fje. Published online December 3, 2002. Aberrant inflammation and resistance to glucocorticoids in Annexin 1 –/ – Mouse , 2022 .
[44] Charles N. Serhan,et al. Resolvin E1 and protectin D1 activate inflammation-resolution programmes , 2007, Nature.
[45] M. Perretti,et al. Evidence for an Anti-Inflammatory Loop Centered on Polymorphonuclear Leukocyte Formyl Peptide Receptor 2/Lipoxin A4 Receptor and Operative in the Inflamed Microvasculature , 2011, The Journal of Immunology.
[46] Y. Lussier,et al. The Emergence of Genome-Based Drug Repositioning , 2011, Science Translational Medicine.
[47] R. Medzhitov. Origin and physiological roles of inflammation , 2008, Nature.
[48] D. Gold,et al. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1 , 2007, Cell Death and Differentiation.
[49] Alexander A. Morgan,et al. Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.
[50] C. Haslett,et al. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. , 2008, Trends in pharmacological sciences.
[51] K. Schulze-Osthoff,et al. Cell Surface Externalization of Annexin A1 as a Failsafe Mechanism Preventing Inflammatory Responses during Secondary Necrosis1 , 2009, The Journal of Immunology.
[52] John Savill,et al. Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.
[53] Christopher Haslett,et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis , 2006, Nature Medicine.
[54] M. Perretti,et al. FPR2/ALX receptor expression and internalization are critical for lipoxin A4 and annexin‐derived peptide‐stimulated phagocytosis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.